Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Cellebrite DI (CLBT) over the last 5 years, with Dec 2024 value amounting to $191.7 million.

  • Cellebrite DI's Cash & Equivalents rose 106.35% to $281.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.4 million, marking a year-over-year increase of 106.35%. This contributed to the annual value of $191.7 million for FY2024, which is 1.13% up from last year.
  • Per Cellebrite DI's latest filing, its Cash & Equivalents stood at $191.7 million for FY2024, which was up 1.13% from $189.5 million recorded in FY2023.
  • Cellebrite DI's Cash & Equivalents' 5-year high stood at $191.7 million during FY2024, with a 5-year trough of $87.6 million in FY2022.
  • In the last 3 years, Cellebrite DI's Cash & Equivalents had a median value of $189.5 million in 2023 and averaged $156.3 million.
  • In the last 5 years, Cellebrite DI's Cash & Equivalents slumped by 39.96% in 2022 and then spiked by 116.23% in 2023.
  • Yearly analysis of 5 years shows Cellebrite DI's Cash & Equivalents stood at $128.7 million in 2020, then rose by 13.41% to $146.0 million in 2021, then crashed by 39.96% to $87.6 million in 2022, then skyrocketed by 116.23% to $189.5 million in 2023, then grew by 1.13% to $191.7 million in 2024.